487 related articles for article (PubMed ID: 36758572)
1. Safety and efficacy of once-weekly basal insulin Fc in people with type 2 diabetes previously treated with basal insulin: a multicentre, open-label, randomised, phase 2 study.
Frias J; Chien J; Zhang Q; Chigutsa E; Landschulz W; Syring K; Wullenweber P; Haupt A; Kazda C
Lancet Diabetes Endocrinol; 2023 Mar; 11(3):158-168. PubMed ID: 36758572
[TBL] [Abstract][Full Text] [Related]
2. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.
Ludvik B; Giorgino F; Jódar E; Frias JP; Fernández Landó L; Brown K; Bray R; Rodríguez Á
Lancet; 2021 Aug; 398(10300):583-598. PubMed ID: 34370970
[TBL] [Abstract][Full Text] [Related]
3. Once-Weekly Basal Insulin Fc Demonstrated Similar Glycemic Control to Once-Daily Insulin Degludec in Insulin-Naive Patients With Type 2 Diabetes: A Phase 2 Randomized Control Trial.
Bue-Valleskey JM; Kazda CM; Ma C; Chien J; Zhang Q; Chigutsa E; Landschulz W; Haupt A; Frias JP
Diabetes Care; 2023 May; 46(5):1060-1067. PubMed ID: 36944059
[TBL] [Abstract][Full Text] [Related]
4. Novel Once-Weekly Basal Insulin Fc Achieved Similar Glycemic Control With a Safety Profile Comparable to Insulin Degludec in Patients With Type 1 Diabetes.
Kazda CM; Bue-Valleskey JM; Chien J; Zhang Q; Chigutsa E; Landschulz W; Wullenweber P; Haupt A; Dahl D
Diabetes Care; 2023 May; 46(5):1052-1059. PubMed ID: 36920867
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.
Battelino T; Bergenstal RM; Rodríguez A; Fernández Landó L; Bray R; Tong Z; Brown K
Lancet Diabetes Endocrinol; 2022 Jun; 10(6):407-417. PubMed ID: 35468321
[TBL] [Abstract][Full Text] [Related]
6. Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial.
Philis-Tsimikas A; Asong M; Franek E; Jia T; Rosenstock J; Stachlewska K; Watada H; Kellerer M
Lancet Diabetes Endocrinol; 2023 Jun; 11(6):414-425. PubMed ID: 37148899
[TBL] [Abstract][Full Text] [Related]
7. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.
Tuttle KR; Lakshmanan MC; Rayner B; Busch RS; Zimmermann AG; Woodward DB; Botros FT
Lancet Diabetes Endocrinol; 2018 Aug; 6(8):605-617. PubMed ID: 29910024
[TBL] [Abstract][Full Text] [Related]
8. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.
Garber AJ; King AB; Del Prato S; Sreenan S; Balci MK; Muñoz-Torres M; Rosenstock J; Endahl LA; Francisco AM; Hollander P;
Lancet; 2012 Apr; 379(9825):1498-507. PubMed ID: 22521072
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.
Aroda VR; Bain SC; Cariou B; Piletič M; Rose L; Axelsen M; Rowe E; DeVries JH
Lancet Diabetes Endocrinol; 2017 May; 5(5):355-366. PubMed ID: 28344112
[TBL] [Abstract][Full Text] [Related]
10. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.
Del Prato S; Kahn SE; Pavo I; Weerakkody GJ; Yang Z; Doupis J; Aizenberg D; Wynne AG; Riesmeyer JS; Heine RJ; Wiese RJ;
Lancet; 2021 Nov; 398(10313):1811-1824. PubMed ID: 34672967
[TBL] [Abstract][Full Text] [Related]
11. Insulin degludec versus insulin detemir, both in combination with insulin aspart, in the treatment of pregnant women with type 1 diabetes (EXPECT): an open‑label, multinational, randomised, controlled, non-inferiority trial.
Mathiesen ER; Alibegovic AC; Corcoy R; Dunne F; Feig DS; Hod M; Jia T; Kalyanam B; Kar S; Kautzky-Willer A; Marchesini C; Rea RD; Damm P;
Lancet Diabetes Endocrinol; 2023 Feb; 11(2):86-95. PubMed ID: 36623517
[TBL] [Abstract][Full Text] [Related]
12. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial.
Mathieu C; Ásbjörnsdóttir B; Bajaj HS; Lane W; Matos ALSA; Murthy S; Stachlewska K; Rosenstock J
Lancet; 2023 Jun; 401(10392):1929-1940. PubMed ID: 37156252
[TBL] [Abstract][Full Text] [Related]
13. Once-Weekly Insulin Icodec vs Once-Daily Insulin Degludec in Adults With Insulin-Naive Type 2 Diabetes: The ONWARDS 3 Randomized Clinical Trial.
Lingvay I; Asong M; Desouza C; Gourdy P; Kar S; Vianna A; Vilsbøll T; Vinther S; Mu Y
JAMA; 2023 Jul; 330(3):228-237. PubMed ID: 37354562
[TBL] [Abstract][Full Text] [Related]
14. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.
Gastaldelli A; Cusi K; Fernández Landó L; Bray R; Brouwers B; Rodríguez Á
Lancet Diabetes Endocrinol; 2022 Jun; 10(6):393-406. PubMed ID: 35468325
[TBL] [Abstract][Full Text] [Related]
15. Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label, treat-to-target trial.
Russell-Jones D; Babazono T; Cailleteau R; Engberg S; Irace C; Kjaersgaard MIS; Mathieu C; Rosenstock J; Woo V; Klonoff DC
Lancet; 2023 Nov; 402(10413):1636-1647. PubMed ID: 37863084
[TBL] [Abstract][Full Text] [Related]
16. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.
Heller S; Buse J; Fisher M; Garg S; Marre M; Merker L; Renard E; Russell-Jones D; Philotheou A; Francisco AM; Pei H; Bode B;
Lancet; 2012 Apr; 379(9825):1489-97. PubMed ID: 22521071
[TBL] [Abstract][Full Text] [Related]
17. Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial.
Diamant M; Van Gaal L; Guerci B; Stranks S; Han J; Malloy J; Boardman MK; Trautmann ME
Lancet Diabetes Endocrinol; 2014 Jun; 2(6):464-73. PubMed ID: 24731672
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
[TBL] [Abstract][Full Text] [Related]
19. Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial.
Zinman B; Fulcher G; Rao PV; Thomas N; Endahl LA; Johansen T; Lindh R; Lewin A; Rosenstock J; Pinget M; Mathieu C
Lancet; 2011 Mar; 377(9769):924-31. PubMed ID: 21396703
[TBL] [Abstract][Full Text] [Related]
20. Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial.
Philis-Tsimikas A; Klonoff DC; Khunti K; Bajaj HS; Leiter LA; Hansen MV; Troelsen LN; Ladelund S; Heller S; Pieber TR;
Diabetologia; 2020 Apr; 63(4):698-710. PubMed ID: 31984443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]